Clinical trials: Candidiasis, Invasive
Chronic Mucocutaneous Candidiasis, Invasive Aspergillosis
Natural History of Individuals With Immune System Problems That Lead to Fungal Infections
Background: The immune system is made up of special cells, tissues, and organs that fight infections. Problems with this system may lead to frequent, severe, or unusual fungal infections.
- Conditions
- Chronic Mucocutaneous Candidiasis, Invasive Aspergillosis, CARD9, APECED
- Trial name
- NCT01386437
- Where
- United States
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Invasive Candidiasis
Comparison of Uncomplicated Candidemia Therapy Duration in Children
The goal of this clinical trial is to compare antifungal therapy duration in pediatric uncomplicated candidemia. The specific aims are: Compare the desirability of outcome ranking in children with uncomplicated candidemia…
- Trial name
- COUNT (NCT05763251)
- Testing
- therapy duration
- Where
- 22 sites in United States, Australia
- Volunteers
- 420 people
- Sponsor
- Arkansas Children's Hospital Research Institute
Invasive Candidiasis
Invasive Candidiasis in Critical Care
The combination of acute phase marker monitoring and the "T2Candida" assay (name of the test) will represent an acceleration of the identification of the causative agent of mycotic infection, a significant improvement in the…
- Trial name
- NCT06456151
- Testing
- Invasive candidiasis test, Urine sample collection for future research
- Where
- 2 sites in Czechia
- Volunteers
- 100 people
- Sponsor
- University Hospital Ostrava
Oropharyngeal Candidiasis, Candidemia
Study of Mycamine® in Children With Fungal Infections to Evaluate Safety and Blood Levels of the Drug
Children with fungal infections will be divided into two groups by weight. Children weighing < 25 kg will receive a higher dose of study medication (per kg body weight) for 10 to 14 days than children weighing > 25 kg.
- Conditions
- Oropharyngeal Candidiasis, Candidemia, Invasive Candidiasis, Esophageal Candidiasis
- Trial name
- NCT00608335
- Testing
- Micafungin
- Where
- 13 sites in United States, South Africa
- Volunteers
- 84 people
- Sponsor
- Astellas Pharma Inc
Candidiasis, Systemic, Candida Meningitis
Determination of Levels of Micafungin in Neonates Suffering From Systemic Candidiasis and/or Candida Meningitis
The primary purpose of this study is to evaluate the pharmacokinetic profile of micafungin administered to neonates suffering from systemic candidiasis.
- Trial name
- NCT03421002
- Testing
- Micafungin
- Where
- 2 sites in Italy
- Volunteers
- 35 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Invasive Fungal Infections
Non-interventional Study for Prevention and Treatment of Fungal Infections in Paediatric Patients in Asia/Oceania - ERADICATE Study
The aim of the study is to prospectively evaluate the safety and efficacy of micafungin when prescribed for prophylaxis or treatment of fungal infections in different real-world clinical conditions and centers, in pediatric…
- Trial name
- NCT03174457
- Testing
- Micafungin
- Where
- 16 sites in Hong Kong, Singapore and 3 more
- Volunteers
- 120 people
- Sponsor
- Astellas Pharma Singapore Pte. Ltd.
Invasive Candidiases
ECMM Candida Registry - CandiReg
The objective of the European Confederation of Medical Mycology - ECMM Candida Registry (CandiReg) is to overcome the lack of knowledge on epidemiology, clinical course, and molecular characteristics of invasive infections due to…
- Trial name
- CandiReg (NCT03450005)
- Where
- Germany
- Volunteers
- 2,000 people
- Sponsor
- University of Cologne
Candida Sepsis, Candidiasis, Invasive
Early Identification of Candida in Intra-abdominal Candidiasis
Intra-abdominal candidiasis remains the first origin of invasive candidiasis in critically ill patients with a mortality up to 60%. This high mortality is partly related to delay of anti-fungal treatment administration.
- Conditions
- Candida Sepsis, Candidiasis, Invasive, Peritonitis Infectious, Critically Ill
- Trial name
- ICCA (NCT05264571)
- Testing
- calscreener, Metabolic profile, optical microscopy
- Where
- France
- Volunteers
- 40 people
- Sponsor
- Central Hospital, Nancy, France
Invasive Candidiases
Efficacy of Prophylactic Fluconazole Therapy in Preterm and Very Low Birth Weight Neonates in Preventing Invasive Fungal Infection.
Invasive fungal infection is detecting candida species in blood, cerebrospinal fluid, or urine. Clinical signs of invasive candidiasis may include lethargy, temperature instability, feeding intolerance, apnea, hypotension…
- Trial name
- NCT05848492
- Testing
- Fluconazole, Saline
- Where
- Pakistan
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- Services Institute of Medical Sciences, Pakistan
Invasive Candidiasis
BIOPIC: Fungal Biomarkers for Diagnosis and Response to Therapy for Pediatric Candidemia
The purpose of the study is to 1) define the operating characteristics of fungal biomarker assays in pediatric patients at high-risk for developing invasive candidiasis, 2) determine the change in fungal biomarker assay results…
- Trial name
- BIOPIC (NCT02220790)
- Where
- 22 sites in United States, Greece and 2 more
- Volunteers
- 515 people
- Sponsor
- Duke University
Pediatric Invasive Candidiasis
PEACE: Pediatric Antifungal Comparative Effectiveness
The overarching objective is to develop new evidence-based treatment guidelines for invasive fungal diseases in children. To accomplish that, this protocol will focus on two specific aims: 1) Compare the effectiveness of…
- Trial name
- PEACE (NCT01869829)
- Testing
- Observational antifungal therapy
- Where
- 35 sites in United States, Canada and 6 more
- Volunteers
- 750 people
- Sponsor
- Duke University
Candidiasis, Invasive
Safety, Tolerability, and Efficacy of Caspofungin Versus Amphotericin B Deoxycholate in the Treatment of Invasive Candidiasis in Neonates and Infants (MK-0991-064)
The study will evaluate the safety, tolerability, and efficacy of caspofungin as compared with amphotericin B deoxycholate in the treatment of invasive candidiasis in neonates and infants.
- Trial name
- NCT01945281
- Testing
- Caspofungin, Amphotericin B Deoxycholate
- Volunteers
- 51 people
- Sponsor
- Merck Sharp & Dohme LLC
Invasive Candidiasis
Pharmacokinetics of Micafungin in Children on Extracorporeal Membrane Oxygenation
Determine proper dosing of micafungin in children supported with extracorporeal membrane oxygenation (ECMO).
- Trial name
- NCT01666769
- Testing
- Micafungin
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Kevin Watt
Candidemia
Study To Assess Pharmacokinetics, Safety & Efficacy of Anidulafungin When Treating Children With Invasive Candidiasis
Prospective, open label study to assess the pharmacokinetics, safety \& efficacy of anidulafungin when used to treat children (aged 1 month - <18 years) with invasive candidiasis, including candidemia (ICC).
- Trial name
- NCT00761267
- Testing
- Anidulafungin, Fluconazole
- Where
- 45 sites in United States, Brazil and 8 more
- Volunteers
- 70 people
- Sponsor
- Pfizer
Candidiasis, Esophageal, Candidiasis, Invasive
A Study of Caspofungin (MK-0991) in Japanese Children and Adolescents With Documented Candida or Aspergillus Infections (MK-0991-074)
The study estimates the safety, efficacy, and pharmacokinetics of caspofungin (MK-0991) in Japanese children and adolescents with documented Candida or Aspergillus infections.
- Conditions
- Candidiasis, Esophageal, Candidiasis, Invasive, Aspergillosis
- Trial name
- NCT01165320
- Testing
- Caspofungin
- Volunteers
- 20 people
- Sponsor
- Merck Sharp & Dohme LLC
Mycoses
Study of Posaconazole in the Treatment of Invasive Fungal Infections (Study P02095)
This study is designed to evaluate the safety, tolerance and efficacy of Posaconazole (SCH 56592) under an open label, treatment protocol for subjects with invasive fungal infections: A.
- Trial name
- NCT00034632
- Testing
- Posaconazole oral suspension
- Sponsor
- Merck Sharp & Dohme LLC
Mycoses
PK/PD Study of Posaconazole for Empiric Treatment of Invasive Fungal Infections in Neutropenic Patients or Treatment of Refractory Invasive Fungal Infections (Study P01893)
This phase II study will be conducted to: 1. evaluate the pharmacokinetics, safety, tolerance, and efficacy of different dosing schedules of Posaconazole in immunocompromised hosts with a variety of refractory invasive fungal…
- Trial name
- NCT00034671
- Testing
- Posaconazole oral suspension
- Volunteers
- 98 people
- Sponsor
- Merck Sharp & Dohme LLC
Invasive Candidiasis, Esophageal Candidiasis
Study of Mycamine® in Infants and Toddlers With Fungal Infections to Evaluate Safety and Blood Levels of the Drug
Infants and toddlers with fungal infections will receive 10 to 14 days of treatment with an antifungal drug. Safety and drug blood levels will be assessed
- Conditions
- Invasive Candidiasis, Esophageal Candidiasis, Oropharyngeal Candidiasis, Candidemia
- Trial name
- NCT00607763
- Testing
- Micafungin (Mycamine)
- Where
- 6 sites in United States
- Volunteers
- 9 people
- Sponsor
- Astellas Pharma Inc
Candidiasis, Fungemia
An Evaluation Of The Effectiveness And Safety Of Anidulafungin Compared To Caspofungin For The Treatment Of Deep Tissue Infection Due To Candida
The purpose of this study is to gather information on the use of anidulafungin for the treatment of serious Candida infection. It is expected that anidulafungin will be at least as safe and as effective as the comparator drug…
- Trial name
- NCT00805740
- Testing
- Active anidulafungin, Active Caspofungin
- Where
- 18 sites in United States, Belgium and 7 more
- Volunteers
- 41 people
- Sponsor
- Pfizer
Fungemia, Neutropenia
An Evaluation Of The Effectiveness And Safety Of Anidulafungin Compared To Caspofungin For The Treatment Of Serious Fungal Infection Due To Candida In Patients With A Dysfunctional Immune System
The purpose of this study is to gather information on the use of anidulafungin for the treatment of Candida infection in patients with an abnormal immune system.
- Conditions
- Fungemia, Neutropenia, Candidiasis
- Trial name
- NCT00806351
- Testing
- Active Anidulafungin, Active Caspofungin
- Where
- 10 sites in Bosnia and Herzegovina, France and 4 more
- Volunteers
- 21 people
- Sponsor
- Pfizer